Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855582 · ClinicalTrials.gov registry record · Phase 3
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
NCT00855582 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 606 participants.
The verdict
NCT00855582, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
Study Summary
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of BPH.
Interventions
- DRUG Placebo
- DRUG Tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855582
The ClinicalTrials.gov registry entry for NCT00855582 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00855582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00855582 about?
NCT00855582 is a clinical study titled "A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia". Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of BPH.
What is the current status of trial NCT00855582?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2009-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00855582?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT00855582?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.